

**REGISTERED NUMBER: 09485187 (England and Wales)**

**REPORT OF THE DIRECTOR AND  
UNAUDITED FINANCIAL STATEMENTS  
FOR THE PERIOD 1 APRIL 2015 TO 31 MARCH 2016  
FOR  
NOXSUDOR THERAPEUTICS LIMITED**

SATURDAY



\*A5YM42AZ\*

A18

21/01/2017

#174

COMPANIES HOUSE

**NOXSUDOR THERAPEUTICS LIMITED**

**CONTENTS OF THE FINANCIAL STATEMENTS  
FOR THE PERIOD 1 APRIL 2015 TO 31 MARCH 2016**

	<b>Page</b>
<b>Company Information</b>	1
<b>Report of the Director</b>	2
<b>Profit and Loss Account</b>	3
<b>Balance Sheet</b>	4
<b>Notes to the Financial Statements</b>	5
<b>Report of the Accountants</b>	6
<b>Profit and Loss Account</b>	7

**NOXSUDOR THERAPEUTICS LIMITED**  
**COMPANY INFORMATION**  
**FOR THE PERIOD 1 APRIL 2015 TO 31 MARCH 2016**

**DIRECTOR:** H L Oakes Jnr  
D J Macfarlane  
T M Steel

**SECRETARY:**

**REGISTERED OFFICE:** 26 Grosvenor Street  
London W1K 4QW

**REGISTERED NUMBER:** 09485187 (England and Wales)

**ACCOUNTANTS:**

**NOXSUDOR THERAPEUTICS LIMITED**

**REPORT OF THE DIRECTOR  
FOR THE PERIOD 1 APRIL 2015 TO 31 MARCH 2016**

The director presents his report with the financial statements of the company for the period 1 APRIL 2015 TO 31 MARCH 2016.

**INCORPORATION**

The company was incorporated on 12 March 2015.

**DIRECTOR**

H L Oakes Jnr held office during the whole of the period from 29 October 2015 to the date of this report.

The director, being eligible, offers himself for election at the forthcoming first Annual General Meeting.

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

**ON BEHALF OF THE BOARD:**



.....  
H L Oakes Jnr - Director

Date: ..... 20 January 2016

**NOXSUDOR THERAPEUTICS LIMITED**  
**PROFIT AND LOSS ACCOUNT**  
**FOR THE PERIOD 1 APRIL 2015 TO 31 MARCH 2016**

	Notes	£
<b>TURNOVER</b>		-
Administrative expenses		<u>(170,461)</u>
<b>OPERATING LOSS and LOSS ON ORDINARY ACTIVITIES BEFORE TAXATION</b>	2	<b>(170,461)</b>
Tax on loss on ordinary activities	3	<u>-</u>
<b>LOSS FOR THE FINANCIAL PERIOD</b>		<b><u>(170,461)</u></b>

The notes form part of these financial statements

NOXSUDOR THERAPEUTICS LIMITED (REGISTERED NUMBER: 09287241)

BALANCE SHEET  
31 March 2016

	Notes	£
<b>CURRENT ASSETS</b>		
Debtors	4	2,000
VAT Receivable		7,695
Cash at bank and in hand		<u>24,871</u>
		<b>34,565</b>
<b>CREDITORS</b>		
Amounts falling due within one year	5	<u>(660)</u>
<b>NET CURRENT LIABILITIES</b>		<u>(660)</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<u><b>33,906</b></u>
<b>CAPITAL AND RESERVES</b>		
Called up share capital	6	1,917
Profit and loss account	7	202,450
		<u>(170,461)</u>
<b>SHAREHOLDERS' FUNDS</b>		<u><b>33,906</b></u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 March 2016.


The members have not required the company to obtain an audit of its financial statements for the period ended 31 March 2016 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

- ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies and with the Financial Reporting Standard for Smaller Entities (effective January 2015).

The financial statements were approved by the director on 20 January 2016 and were signed by:

  
.....  
H L Oakes Jnr - Director

The notes form part of these financial statements

**NOXSUDOR THERAPEUTICS LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE PERIOD 1 APRIL 2015 TO 31 MARCH 2016**

**1. ACCOUNTING POLICIES**

**Accounting convention**

The financial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective January 2015).

**2. OPERATING LOSS**

The operating loss is stated after charging:

	£
Director's remuneration and other benefits etc	<u>          -</u>

**3. TAXATION**

**Analysis of the tax charge**

No liability to UK corporation tax arose on ordinary activities for the period.

**4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	£
Other Debtor -	<u>          2,000</u>
	<u>          2,000</u>

**5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	£
Other creditors -	<u>          660</u>

**6. CALLED UP SHARE CAPITAL**

Allotted, issued and fully paid:

Number:	Class:	Nominal value:	£
1,916,898	Ordinary	£0.001	<u>          1,917</u>

**7. RESERVES**

	<b>Profit and loss account</b>
	<b>£</b>
Deficit for the period	<b>(170,461)</b>
At 31 March 2016	<b><u>(170,461)</u></b>

**NOXSUDOR THERAPEUTICS LIMITED**

**REPORT OF THE ACCOUNTANTS TO THE DIRECTOR OF  
NOXSUDOR THERAPEUTICS LIMITED**

As described on the balance sheet you are responsible for the preparation of the financial statements for the period ended 31 October 2015 set out on pages three to five and you consider that the company is exempt from an audit.

In accordance with your instructions, we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and information and explanations supplied to us.

Date: .....

*20 January 2016*

**NOXSUDOR THERAPEUTICS LIMITED**  
**PROFIT AND LOSS ACCOUNT**  
**FOR THE PERIOD 1 APRIL 2015 TO 31 MARCH 2016**

	£	£
<b>Income</b>		-
Office Expense		9,429
Professional Services		2,124
<b>Product development</b>		
Direct		8,822
Contractors		70,616
<b>Product license Fees</b>		60,000
<b>Finance costs</b>		
Bank charges		824
Advisors		<u>18,646</u>
<b>NET LOSS</b>		<u>(170,461)</u>

This page does not form part of the statutory financial statements